中国创新药巨龙的攀登:从对外授权走向全球扎根

21世纪经济报道
Aug 06

21世纪经济报道记者季媛媛、韩利明孙飘扬站在恒瑞医药发展的舵位上,多年前便勾勒出一幅清晰的航线图:中国创新药出海,将倚重两条主航道——积极的商务拓展(BD),以及核心的“License-out”(对外授权)。如今,这幅蓝图正从纸面缓缓驶入现实的海域。2018至2024这六年航程,恒瑞已悄然完成了13笔对外授权交易。这些合约背后,潜藏着一组惊人的数字:涉及16个分子实体,潜在总交易额约为140亿美元...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10